Longitude leads £25m Kandy Therapeutics series-C

Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed Advisors also took part in the round.

The company will advance the development of NT-814, its non-hormonal drug for the treatment of menopausal symptoms, to a multi-country testing phase. It will initiate the recruitment of patients across the UK, US and Canada in Q4 2018, and is targeting late 2019 for the publication of results related to the process.

Kandy appointed Jo Craig as head of chemistry manufacturing and controls in June this year. Craig left her role as GlaxoSmithKline vice-president of technology, strategy, product development and supply.

Previous funding
The funding round comes less than a year after Advent, Fountain, Forbion and Orbimed provided an undisclosed amount of capital to support the launch of the company.

Company
Founded in September 2017, Stevenage-headquartered Kandy is a biotech company specialising in female sex-hormone-related conditions.

People
Longitude Capital – Josh Richardson (managing director).
Kandy Therapeutics – Mary Kerr (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Advent Venture Partners
• Venture